drugset / Trial / NCT02805205

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia

NCT02805205

Phase 4 Completed 484 enrolled CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.

Timeline

Start
2013-04
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 100 ug/kg Subcutaneous

Indications